Insmed Inc

NASDAQ: INSM
$25.27
+$1.16 (+4.8%)
Closing price April 23, 2024
Insmed Inc is a biopharmaceutical firm focused on developing and marketing treatments for patients with serious and rare diseases globally. Its flagship product, ARIKAYCE, targets Mycobacterium avium complex lung disease in adults. The company is also working on Brensocatib for bronchiectasis and other diseases, and Treprostinil Palmitil Inhalation Powder for certain types of pulmonary hypertension. Founded in 1988, Insmed is based in Bridgewater, New Jersey, serving patients in the US, Europe, Japan, and beyond.

Thursday's Top Analyst Upgrades and Downgrades: Alphabet, Disney, Eli Lilly, Etsy, Microsoft, Mosaic, NetApp, RTX, Spotify and More
Thursday's top analyst upgrades and downgrades included Alphabet, Eli Lilly, Etsy, Microsoft, Mosaic, NetApp, Omega Healthcare Investors, RTX, Sherwin-Williams, Spotify Technology, Walt Disney and WW...
Lee Jackson
Published:

Thursday's Top Analyst Upgrades and Downgrades: Airbnb, Applied Materials, Carvana, Southwestern Energy, Stitch Fix, StoneCo, TripAdvisor and More
Thursday's top analyst upgrades and downgrades included Airbnb, Applied Materials, AutoZone, BorgWarner, Carvana, Dominion Energy, EQT, MongoDB, NRG Energy, PagSeguro Digital, Southwestern Energy,...
Lee Jackson
Published:

Wednesday's Top Analyst Upgrades and Downgrades: eBay, EOG, Etsy, Global Payments, JPMorgan, MetLife, Otis, Salesforce, Wayfair and More
Wednesday's top analyst upgrades and downgrades included Albemarle, Camping World, eBay, EOG Resources, Etsy, Global Payments, IMAX, JPMorgan Chase, MetLife, Otis Worldwide, Salesforce, Wayfair and...
Lee Jackson
Published:

Thursday's Top Analyst Upgrades and Downgrades: Alphabet, ADM, Capital One, Chipotle, Corning, Microsoft, PepsiCo, Spotify, Texas Instruments, Visa and More
Thursday's top analyst upgrades and downgrades included Alphabet, Allstate, Antero Midstream, Archer Daniels Midland, Capital One Financial, Chipotle Mexican Grill, Corning, Microsoft, PepsiCo,...
Lee Jackson
Published:

7 Large Biotechs Expected to Outperform This Earnings Season
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic...
Chris Lange
Published: